

Dear Reviewers and Editors,

Great thanks to you and the anonymous referees for the time and efforts you spent on our manuscript entitled "Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy" and the potential consideration for publication in the World journal of clinical cases.

According to the comments, we have revised the manuscript and would like to resubmit it for your consideration. We have addressed the comments raised by the reviewers, and the amendments are highlighted in the revised manuscript. Point-by-point responses to the reviewers' comments are listed below this letter.

We sincerely hope that this revised manuscript has addressed all your comments and suggestions. We appreciated for reviewers' warm work earnestly, and hope that the correction will meet with approval. Once again, thank you very much for your comments and suggestions.

Yours sincerely,  
YONGZHE

We would like to express our sincere thanks to the reviewers and editors for the constructive comments. We believe that the comments have been very useful to improve the quality of the manuscript.

### **Replies to Editors and Reviewers**

#### **Reviewer 1**

##### **Specific Comments to Authors**

1. Oncologists have seen a lot of descriptions of the side effects of immune checkpoint inhibitors, and it seems obvious. Dare to list the very recent new knowledge that you want to convey in this minireview that has not been found so far. If you don't have new knowledge, please add a new one. Also, add a new Table(s) that summarizes it.

##### **Answer:**

Thank you very much for your suggestion. We have added a new discussion of the effect of COVID-19 on irAEs in lymphoma patients treated with PD-1

inhibitors for immunotherapy and revised parts of this minireview according to your suggestion. Changes have been made to make the expression clearer and more accurate. (Page 18, Line 4)

We have been actively thinking about ways to add a table that summarizes this knowledge, such as our attempts to summarize the mechanisms of PD-1 inhibitors or the mechanisms and characteristics of irAEs induced by PD-1 inhibitors for lymphoma immunotherapy. However, we have not found a form that expresses this knowledge very well yet. We intend to continue this exploration of irAEs in hematologic malignancies and other aspects in a follow-up paper.

2. The side effects of immune checkpoint inhibitors are wide-ranging. Add new schematic figures summarizing them in a way that WJCC readers can understand.

**Answer:**

Thanks for your constructive suggestion. We added a figure to summarize the immune-related adverse events induced by PD-1 inhibitors in lymphoma (Figure 1), and we're hoping that it will improve the quality of the manuscript.

3. The summary is long, especially the second half is poor. It is a poor description that does not match the review of ordinary medical papers. Lastly, it says, “These points need special attention.” Please list what “these points” are. Please revise it.

**Answer:**

Thank you for the comment. We modified the summary and rewrote the second part to make the narrative related to irAEs induced by PD-1 inhibitors in lymphoma more detailed. (Page 3, Line 17)

The revised summary can better express the main points of this review.

**Reviewer 2**

Specific Comments to Authors

1. Dear Authors, Thank you for sharing this useful review. Good luck.

**Answer:** Thank you.